Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach


Halter, J., Schüpbach, W.M.M., Casali, C., Elhasid, R., Fay, K., Hammans, S., Illa, I., Kappeler, L., Krähenbühl, S., Lehmann, T., Mandel, H., Marti, R., Mattle, H., Orchard, K., Savage, D., Sue, C. M., Valcarcel, D., Gratwohl, A. and Hirano, M. (2011) Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach Bone Marrow Transplantation, 46, (3), pp. 330-337. (doi:10.1038/bmt.2010.100).

Download

[img] PDF bmt2010100a.pdf - Other
Restricted to Repository staff only

Download (328kB)

Description/Abstract

Allogeneic hematopoietic SCT (HSCT) has been proposed as a treatment for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). HSCT has been performed in nine patients using different protocols with varying success. Based on this preliminary experience, participants of the first consensus conference propose a common approach to allogeneic HSCT in MNGIE. Standardization of the transplant protocol and the clinical and biochemical assessments will allow evaluation of the safety and efficacy of HSCT as well as optimization of therapy for patients with MNGIE.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1038/bmt.2010.100
ISSNs: 0268-3369 (print)
Related URLs:
Subjects:
Organisations: Cancer Sciences
ePrint ID: 341438
Date :
Date Event
May 2011Published
Date Deposited: 25 Jul 2012 10:48
Last Modified: 17 Apr 2017 16:47
Further Information:Google Scholar
URI: http://eprints.soton.ac.uk/id/eprint/341438

Actions (login required)

View Item View Item